MedTrace Logo

Integrin α6-targeted SPECT Imaging of Breast Cancer

NCT04289532 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-03-06

No results posted yet for this study

Summary

A novel radiotracer 99mTc-RWY targeting Integrin α6 was developed, and the pilot first-in-human study for SPECT imaging of breast cancer was performed in seven healthy volunteers and two breast cancer patients to assess the safety and potential clinical applications of 99mTc-RWY.

Conditions

Interventions

DRUG

99mTc-RWY

99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .

Sponsors & Collaborators

  • China-Japan Union Hospital, Jilin University

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Peking University

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-08
Primary Completion
2019-06-01
Completion
2019-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04289532 on ClinicalTrials.gov